Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)

Summary

  • Interferon- and ribavirin-free DAA regimens recommended for the treatment of HCV infection in patients coinfected with HIV have shown to be highly tolerable with generally favorable safety profiles
  • The most important safety consideration for HCV therapy in patients with HCV/HIV coinfection are established and potential drug–drug interactions between HCV DAAs and antiretroviral agents

Action required